James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Why RadioShack Stock May Be a Lost Cause

Investors mulling a stake in RadioShack stock to play the potential turnaround may want to dissect a couple of alarming details.

Russell 2000 Death Cross: Chill Out!

The Russell 2000 has just hit a death cross, but should traders act on this supposedly ominous clue without question?

Big Pharma Might Finally Be Over the Alzheimer’s Hump

Investing in Alzheimer's disease hasn't been easy (or profitable) in years, but a brighter future for Big Pharma is around the proverbial corner.

Sears’ March to Oblivion Continues With the Eddie Lampert Loan

Sears Holdings is borrowing money from a lender that would be better off if the retailer defaulted. SHLD stock holders may want to ask why.

The One Investing Lesson You Can Learn From Apple AND RadioShack

Anyone who currently owns, or plans to own, AAPL or RSH stock (or both, or even neither!) needs to embrace this key reality.

3 Healthcare Acquisitions Google Should Consider

The best way for Google to make an even bigger splash in healthcare is through smart acquisitions like these 3 companies.

5 Value Stocks to Buy Now

Investors looking for some new stocks to buy may want to consider these value stocks first.

Merck’s Keytruda Win Signals a Big Shift for Big Pharma

MRK per-share profits and revenue are poised to rebound now that its research and development efforts are getting traction.

Best $5 Stocks to Buy Now

Traders looking for new stocks to buy should start the search with stocks under $5 per share. Here are 5 of the best stocks in that price range.

Atlantic City Closings a Grave Omen for Casino Stocks

Casino stocks have been hit-and-miss for a while, but recent abdications suggest we're entering a rough patch.